ELEGANCE Registry: Increasing Clinical Evidence of Drug-Eluting Devi…

Boston Scientific

E. Secemsky

What not to leave behind? A surgical view of reintervention

Boston Scientific

Y. Gouëffic

Clinical Update in Drug Eluting Technologies for PAD

Boston Scientific

P. Monteleone

NCVH Live Case: IVUS-Guided Atherectomy and DCB + DES for SFA

Boston Scientific

N. Petruzzi, P. Nair, S. Noor, S. Henao

Data Driven Decision Making in PAD

Boston Scientific

A. Dua, M. Jaff, B. Wiechmann, R. Sachar

Data Driven Decision Making: New EMINENT and RANGER II SFA Evidence …

Boston Scientific

A. Dua, R. Sachar, M. Jaff, B. Wiechmann

The Next Generation of Drug-Coated Balloon: Ranger™ Drug-Coated PTA …

Boston Scientific

COMPARE Trial Perspectives

Boston Scientific

D. Scheinert

Ranger DCB Platform and Compatibility

Boston Scientific

N. Shammas

Boston Scientific Drug-Eluting Technologies

Boston Scientific

R. Sachar

Dr. Lookstein IMPERIAL 2-Year Data

Boston Scientific

R. Lookstein

Drug-Eluting Stents: The Challenge

Boston Scientific

L. Garcia, M. Jaff, R. Lookstein

Drug-Eluting Stents: The Solution

Boston Scientific

J. Granada, M. Montero-Baker, A. Holden, G. Ansel

Drug-Eluting Stents: The Heritage

Boston Scientific

G. Ansel, M. Jaff, R. Lookstein, J. Diaz-Cartelle

Drug-Eluting Stents: The Data

Boston Scientific

J. Diaz-Cartelle, R. Lookstein, L. Garcia

Drug-Eluting Stents: The Breakthrough

Boston Scientific

A. Holden, W. Gray, R. Lookstein, T. Zeller

IMPERIAL Trial: First of its Kind Design

Boston Scientific

W. Gray, R. Lookstein, M. Jaff

Impact of the IMPERIAL Trial

Boston Scientific

M. Jaff, W. Gray, R. Lookstein, S. Henao, G. Ansel

ELEGANCE Registry: Increasing Clinical Evidence of Drug-Eluting Devi…

Boston Scientific

E. Secemsky

The Challenges of the SFA

Boston Scientific